GlycoMimetics (NASDAQ:GLYC) and Immunic (NASDAQ:IMUX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends and valuation.
Valuation and Earnings
This table compares GlycoMimetics and Immunic’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
Immunic is trading at a lower price-to-earnings ratio than GlycoMimetics, indicating that it is currently the more affordable of the two stocks.
This is a summary of recent ratings for GlycoMimetics and Immunic, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
GlycoMimetics presently has a consensus target price of $13.00, suggesting a potential upside of 460.34%. Immunic has a consensus target price of $59.56, suggesting a potential upside of 315.60%. Given GlycoMimetics’ higher probable upside, analysts plainly believe GlycoMimetics is more favorable than Immunic.
Risk and Volatility
GlycoMimetics has a beta of 2.46, indicating that its share price is 146% more volatile than the S&P 500. Comparatively, Immunic has a beta of 2.21, indicating that its share price is 121% more volatile than the S&P 500.
This table compares GlycoMimetics and Immunic’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider and Institutional Ownership
82.2% of GlycoMimetics shares are held by institutional investors. Comparatively, 41.3% of Immunic shares are held by institutional investors. 26.8% of GlycoMimetics shares are held by company insiders. Comparatively, 12.1% of Immunic shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
GlycoMimetics beats Immunic on 8 of the 10 factors compared between the two stocks.
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company's drug candidate include rivipansel, a pan-selectin antagonist for the treatment of vaso-occlusive crisis in sickle cell disease. It is also developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as Phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359 to target E-selectin and a chemokine receptors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin; and Galectin-3, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and collaboration and license agreement with Apollomics for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was founded in 2003 and is headquartered in Rockville, Maryland.
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.
Receive News & Ratings for GlycoMimetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics and related companies with MarketBeat.com's FREE daily email newsletter.